The Joint Corp. (NASDAQ:JYNT) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET

Company Participants

Kirsten Chapman - Investor Relations

Peter Holt - President and Chief Executive Officer

Jake Singleton - Chief Financial Officer

Conference Call Participants

Jeremy Hamblin - Craig-Hallum Capital Group

Jeff Van Sinderen - B. Riley

Thomas McGovern - Maxim Group

George Kelly - ROTH MKM

Operator

Hello, and welcome to The Joint Corp. Second Quarter 2023 Financial Results Conference Call. [Operator Instruction] Please note this event is being recorded. I would now like to turn the conference over to Kirsten Chapman of LHA Investor Relations. Please go ahead.

Kirsten Chapman

Thank you, MJ. Good afternoon, everyone. This is Kirsten Chapman of LHA Investor Relations. Joining us on the call today are President and CEO, Peter Holt and CFO, Jake Singleton. Please note we are using a slide presentation that can be found at ir.thejoint.com. Today, after the close of market, the Joint issued its operating metrics for the quarter ended June 30, 2023. If you do not already have a copy of this press release, it can be found in the Investor Relations section of the company’s website.

As provided on Slide 2, please be advised that today’s discussion includes forward-looking statements, including statements concerning our strategy, future operations, future financial position and plans and objectives of management.

Throughout today’s discussion, we will present some important factors relating to our business that could affect these forward-looking statements. The forward-looking statements are made based on current predictions, expectations, estimates and assumptions and are also subject to risks and uncertainties that may cause actual results to differ materially from statements we make today. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics. Due in part to the nation-wide labor shortage, an increase in operating expenses due to measures we may need to take to address such shortage inflation, exasperated by COVID-19 and the current War in Ukraine, which has increased our cost and which could otherwise negatively impact our business, the potential for further disruption to our operations and predictable impact on our business of the COVID-19 outbreak and outbreaks of other contagious diseases. Our failure to develop or acquire company-owned or managed clinics as rapidly as we intend. Our failure to possibly operate company-owned or managed clinics short selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and resulting class action lawsuits.